The demise of Combidex / Sinerem

Posted on March 24, 2010 by Sitemaster

For several years a company initially called Advanced Magnetics (and later known as AMAG Pharma), with its partners, spent a good deal of money developing and seeking approval of a product called ferumoxtran-10.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | 35 Comments »

Prostate cancer news reports: Tuesday, June 30, 2009

Posted on June 30, 2009 by Sitemaster

In todayas news reports we deal with items about: Celecoxib therapy prior to radical prostatectomy for cT1-2 disease Sentinel lymph node dissection (again) Surgical decompression and spinal reconstruction in man with spinal metastasis

Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: , , , , , , , | Leave a Comment »

Sentinel lymph node dissection in prostate cancer

Posted on June 26, 2009 by Sitemaster

A technique known as sentinel lymph node dissection (SLND) has replaced extended lymphadenectomy for nodal staging in several types of solid tumor cancers.

Filed under: Diagnosis, Management, Risk | Tagged: , , | Leave a Comment »

Combidex, MRI, and identification of nodal metastases

Posted on June 17, 2009 by Sitemaster

One of the major issues in the management of prostate cancer is the identification of early physical (as opposed to biochemical) evidence of metastatic disease.

Filed under: Diagnosis, Drugs in development, Management, Risk | Tagged: , , , , | 2 Comments »

Follow

Get every new post delivered to your Inbox.

Join 269 other followers